All Stories

  1. Sex-related differences in within-subject biological variation estimates for 22 essential and non-essential amino acids
  2. Biological variation of inflammatory and iron metabolism markers in high-endurance recreational athletes; are these markers useful for athlete monitoring?
  3. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
  4. Biological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individuals
  5. Biological variation: recent development and future challenges
  6. Critical review and meta-analysis of biological variation estimates for tumor markers
  7. Long-term within- and between-subject biological variation of 29 routine laboratory measurands in athletes
  8. Biological variation estimates of thyroid related measurands – meta-analysis of BIVAC compliant studies
  9. Evidence-Based Introduction of Large-Scale Medical Technology Into Healthcare Through Test of Chance and Proof of Concept
  10. The European Biological Variation Study (EuBIVAS): a summary report
  11. Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study
  12. Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12® (holotranscobalamin) in the diagnosis of vitamin B12 deficiency
  13. Biological Variation of Cardiac Troponins in Health and Disease: A Systematic Review and Meta-analysis
  14. Critical appraisal and meta-analysis of biological variation estimates for kidney related analytes
  15. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  16. Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care
  17. Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC)
  18. European Biological Variation Study (EuBIVAS): Within- and Between-Subject Biological Variation Data for 15 Frequently Measured Proteins
  19. Systematic review of the biological variation data for diabetes related analytes
  20. The EuBIVAS: Within- and Between-Subject Biological Variation Data for Electrolytes, Lipids, Urea, Uric Acid, Total Protein, Total Bilirubin, Direct Bilirubin, and Glucose
  21. PTU-132 Normal alt – missed opportunities to find fibrosis. lessons from ILFT
  22. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects
  23. Intelligent liver function diagnostic pathway – Relevance of alanine transaminase normal values
  24. Harmonization initiatives in the generation, reporting and application of biological variation data
  25. Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the ‘intelligent LFT’ pathway for the automated assessment of deranged liver enzymes
  26. Intelligent Liver Function Testing (iLFT): A Trial of Reflex Testing, Automated Diagnosis and Staging of Liver Disease
  27. A Critical Appraisal Checklist (BIVAC), to evaluate paper on Biological Variation
  28. Biological variation of serum creatinine
  29. Biological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum
  30. Sample collections from healthy volunteers for biological variation estimates’ update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine
  31. Biological variation: a still evolving facet of laboratory medicine
  32. A checklist for critical appraisal of studies of biological variation
  33. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase
  34. Reflex and reflective testing: efficiency and effectiveness of adding on laboratory tests
  35. UK Consensus Conference on Early Chronic Kidney Disease 6 and 7 February 2007
  36. Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activityin VivoLimits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis
  37. Association between the cholesteryl ester transfer protein TaqI-detectable B polymorphism and low high-density lipoprotein cholesterol concentration in Saudis
  38. Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease
  39. 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
  40. Cardiovascular risk assessment in patients with retinal vein occlusion
  41. Osteoblastic 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure
  42. Role of leptin in glucose metabolism in type 2 diabetes
  43. Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease, in Saudi Arabians
  44. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus
  45. The sleep apnoea/hypopnoea syndrome depresses waking vagal tone independent of sympathetic activation
  46. Comparative accuracy of cardiovascular risk prediction methods in primary care patients
  47. Assessment of coronary heart disease risk prediction in general practice-which table?
  48. Standardization of HbA1c measurements
  49. Laboratory‐based calculation of coronary heart disease risk in a hospital diabetic clinic
  50. Plasma total homocysteine measurement by ion-paired reversed-phase hplc with electrochemical detection
  51. Glomerular filtration rate determination in diabetic patients using iohexol clearance — comparison of single and multiple plasma sampling methods
  52. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population
  53. A Non-Isotopic Method for Estimating 11β Hydroxysteroid Dehydrogenase Activity In Vivo
  54. Ethnic differences in outcome of serum screening for Down's syndrome
  55. Measurement presents technical difficulties
  56. Plasma angiotensin-converting enzyme activity and carotid wall thickening.
  57. Serum screening for Down's syndrome. Vacutainer system can lead to inaccurate results.
  58. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia
  59. Re‐evaluation of the captopril test for the diagnosis of primary hyperaldosteronism
  60. A case of skin hyperpigmentation due to α-MSH hypersecretion
  61. Interference of Fluorescein with Creatinine Assays
  62. Effects of mobile phase composition on the chromatographic and electrochemical behaviour of catecholamines and selected metabolites
  63. DOSE REGIMENS OF HUMAN GROWTH HORMONE: EFFECTS OF CONTINUOUS INFUSION AND OF A GELATIN VEHICLE ON GROWTH IN RATS AND RATE OF ABSORPTION IN RABBITS
  64. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication
  65. 2.4 Biological variation data: the need for appraisal of the evidence base